Akari Therapeutics Enters and Terminates Agreements
Ticker: AKTX · Form: 8-K · Filed: Aug 21, 2025 · CIK: 1541157
| Field | Detail |
|---|---|
| Company | Akari Therapeutics PLC (AKTX) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2,261,000, $2,826,250, $1,250,000, $1,000,000 |
| Sentiment | mixed |
Sentiment: mixed
Topics: material-agreement, agreement-termination, financial-obligation
Related Tickers: AKTX
TL;DR
Akari Therapeutics just signed and broke a deal on the same day. Big moves happening.
AI Summary
Akari Therapeutics Plc entered into a material definitive agreement on August 15, 2025. The company also terminated a material definitive agreement on the same date. These events create direct financial obligations or obligations under an off-balance sheet arrangement for the registrant.
Why It Matters
The company's entry into and termination of material agreements on the same day suggests significant strategic shifts or negotiations that could impact its financial obligations and future operations.
Risk Assessment
Risk Level: medium — The simultaneous entry into and termination of material agreements indicates potential volatility or significant strategic changes that could affect the company's financial health and operational direction.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
FAQ
What was the nature of the material definitive agreement entered into by Akari Therapeutics Plc?
The filing states that Akari Therapeutics Plc entered into a material definitive agreement on August 15, 2025, but does not specify its nature.
What was the reason for the termination of the material definitive agreement?
The filing indicates that Akari Therapeutics Plc terminated a material definitive agreement on August 15, 2025, but does not provide the reason for the termination.
What are the specific financial obligations created by these agreements?
The filing notes the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant as a result of these agreements, but does not detail the specific amounts or terms.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 15, 2025.
What is Akari Therapeutics Plc's Standard Industrial Classification (SIC) code?
Akari Therapeutics Plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,015 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-08-21 17:00:42
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
- $2,261,000 — tes with an aggregate purchase price of $2,261,000 and an aggregate principal amount of $2
- $2,826,250 — 00 and an aggregate principal amount of $2,826,250, inclusive of a note exchange with the
- $1,250,000 — hased a Note with a principal amount of $1,250,000 for a purchase price of $1,000,000, wit
- $1,000,000 — t of $1,250,000 for a purchase price of $1,000,000, with the purchase price thereof to be
- $162,567 — to be satisfied through the payment of $162,567 in cash and the cancellation of $837,43
- $837,433 — 162,567 in cash and the cancellation of $837,433 of outstanding principal and accrued in
- $1.4 million — al gross cash proceeds of approximately $1.4 million to Paulson Investment Company ("Paulson
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 29KB
- 0001641172-25-025104.txt ( ) — 284KB
- aktx-20250815.xsd (EX-101.SCH) — 4KB
- aktx-20250815_def.xml (EX-101.DEF) — 26KB
- aktx-20250815_lab.xml (EX-101.LAB) — 36KB
- aktx-20250815_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: August 21, 2025 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer